Research Article: Neglected Disease Research and Development: How Much Are We Really Spending?

Date Published: February 3, 2009

Publisher: Public Library of Science

Author(s): Mary Moran, Javier Guzman, Anne-Laure Ropars, Alina McDonald, Nicole Jameson, Brenda Omune, Sam Ryan, Lindsey Wu

Abstract: Mary Moran and colleagues survey global investment into research and development of new pharmaceutical products to prevent, manage, or cure diseases of the developing world.

Partial Text: The need for new pharmaceutical tools to prevent and treat neglected diseases is widely accepted [1]. The creation of a vaccine for HIV/AIDS, more effective diagnostics for tuberculosis (TB), and better treatments for leishmaniasis and sleeping sickness would greatly improve health in the developing world in line with the United Nations Millennium Development Goals. However, funders wishing to invest in this vitally important area currently face an information gap.

The chief principle of the G-FINDER survey was to provide consistent, comparable, comprehensive data on neglected disease R&D investments to those working in the field.

Neglected disease R&D is conducted by a wide variety of organisations, including academic groups, public institutions, and private companies. Some rely entirely on external grants for their neglected disease R&D programmes, while others fund their programmes from their own budgets, and yet others operate on a mix of both.



Leave a Reply

Your email address will not be published.